To investigate the safety and effectiveness of anlotinib in combination with chemotherapy that contains carboplatin/ pemetrexed, followed by maintenance therapy (anlotinib + pemetrexed), a clinical trial was carried out in advanced EGFR/ALK wild-type nsq-NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.